Literature DB >> 25680753

A novel method for analyzing extremely biased agonism at G protein-coupled receptors.

Edward L Stahl1, Lei Zhou2, Frederick J Ehlert2, Laura M Bohn2.   

Abstract

Seven transmembrane receptors were originally named and characterized based on their ability to couple to heterotrimeric G proteins. The assortment of coupling partners for G protein-coupled receptors has subsequently expanded to include other effectors (most notably the βarrestins). This diversity of partners available to the receptor has prompted the pursuit of ligands that selectively activate only a subset of the available partners. A biased or functionally selective ligand may be able to distinguish between different active states of the receptor, and this would result in the preferential activation of one signaling cascade more than another. Although application of the "standard" operational model for analyzing ligand bias is useful and suitable in most cases, there are limitations that arise when the biased agonist fails to induce a significant response in one of the assays being compared. In this article, we describe a quantitative method for measuring ligand bias that is particularly useful for such cases of extreme bias. Using simulations and experimental evidence from several κ opioid receptor agonists, we illustrate a "competitive" model for quantitating the degree and direction of bias. By comparing the results obtained from the competitive model with the standard model, we demonstrate that the competitive model expands the potential for evaluating the bias of very partial agonists. We conclude the competitive model provides a useful mechanism for analyzing the bias of partial agonists that exhibit extreme bias.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Mesh:

Substances:

Year:  2015        PMID: 25680753      PMCID: PMC4407734          DOI: 10.1124/mol.114.096503

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  44 in total

1.  A simple method for quantifying functional selectivity and agonist bias.

Authors:  Terry Kenakin; Christian Watson; Vanessa Muniz-Medina; Arthur Christopoulos; Steven Novick
Journal:  ACS Chem Neurosci       Date:  2011-12-20       Impact factor: 4.418

2.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.

Authors:  Celine Valant; Lauren T May; Luigi Aurelio; Chung Hui Chuo; Paul J White; Jo-Anne Baltos; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-11       Impact factor: 11.205

Review 3.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

Review 4.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

Review 5.  Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.

Authors:  J A Boening; O M Lesch; R Spanagel; J Wolffgramm; M Narita; D Sinclair; B J Mason; G A Wiesbeck
Journal:  Alcohol Clin Exp Res       Date:  2001-05       Impact factor: 3.455

6.  A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

7.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

Authors:  David M Mottola; Jason D Kilts; Mechelle M Lewis; Hilary S Connery; Q David Walker; Sara R Jones; Raymond G Booth; Deborah K Hyslop; Monford Piercey; R Mark Wightman; Cindy P Lawler; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Authors:  Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

9.  A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Authors:  B J Mason; E C Ritvo; R O Morgan; F R Salvato; G Goldberg; B Welch; E Mantero-Atienza
Journal:  Alcohol Clin Exp Res       Date:  1994-10       Impact factor: 3.455

10.  First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.

Authors:  David G Soergel; Ruth Ann Subach; Conrad L Cowan; Jonathan D Violin; Michael W Lark
Journal:  J Clin Pharmacol       Date:  2013-06-29       Impact factor: 3.126

View more
  33 in total

1.  Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists.

Authors:  David Winpenny; Mellissa Clark; Darren Cawkill
Journal:  Br J Pharmacol       Date:  2016-03-01       Impact factor: 8.739

Review 2.  Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.

Authors:  Louis M Luttrell; Stuart Maudsley; Laura M Bohn
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

3.  Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.

Authors:  Phong M Truong; Sergio A Hassan; Yong-Sok Lee; Theresa A Kopajtic; Jonathan L Katz; Aaron M Chadderdon; John R Traynor; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Bioorg Med Chem       Date:  2017-03-01       Impact factor: 3.641

4.  Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.

Authors:  Nicole M Kennedy; Cullen L Schmid; Nicolette C Ross; Kimberly M Lovell; Zhizhou Yue; Yen Ting Chen; Michael D Cameron; Laura M Bohn; Thomas D Bannister
Journal:  J Med Chem       Date:  2018-09-24       Impact factor: 7.446

5.  Approaches to Assess Biased Signaling at the CB1R Receptor.

Authors:  Robert B Laprairie; Edward L Stahl; Laura M Bohn
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

6.  Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors.

Authors:  Anita K Nivedha; Christofer S Tautermann; Supriyo Bhattacharya; Sangbae Lee; Paola Casarosa; Ines Kollak; Tobias Kiechle; Nagarajan Vaidehi
Journal:  Mol Pharmacol       Date:  2018-01-24       Impact factor: 4.436

7.  Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.

Authors:  Tarsis F Brust; Jenny Morgenweck; Susy A Kim; Jamie H Rose; Jason L Locke; Cullen L Schmid; Lei Zhou; Edward L Stahl; Michael D Cameron; Sarah M Scarry; Jeffrey Aubé; Sara R Jones; Thomas J Martin; Laura M Bohn
Journal:  Sci Signal       Date:  2016-11-29       Impact factor: 8.192

Review 8.  The Opioid Crisis and the Future of Addiction and Pain Therapeutics.

Authors:  Nathan P Coussens; G Sitta Sittampalam; Samantha G Jonson; Matthew D Hall; Heather E Gorby; Amir P Tamiz; Owen B McManus; Christian C Felder; Kurt Rasmussen
Journal:  J Pharmacol Exp Ther       Date:  2019-09-03       Impact factor: 4.030

9.  Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics.

Authors:  Cullen L Schmid; Nicole M Kennedy; Nicolette C Ross; Kimberly M Lovell; Zhizhou Yue; Jenny Morgenweck; Michael D Cameron; Thomas D Bannister; Laura M Bohn
Journal:  Cell       Date:  2017-11-16       Impact factor: 41.582

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.